Navigation Links
VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
Date:8/4/2009

MOUNTAIN VIEW, Calif., Aug. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Canaccord Adams 29th Annual Global Growth Conference in Boston.

The VIVUS presentation will take place at the Intercontinental Hotel on Thursday, August 13, 2009 at 8:30 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://www.wsw.com/webcast/canaccord/vvus or http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

<
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. VIVUS to Present at the Needham and Company Life Sciences Conference
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS Reports First Quarter 2009 Financial Results and Highlights
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
8. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
9. Patent Awarded for a New X-ray Imaging Technology with Capability Unrealized with Present Day Radiological Modalities
10. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
11. Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., REYKJAVIK, Iceland, November 24 /PRNewswi...GN ) today announced the approval of all of its,"f... the District of Delaware,(the "Bankruptcy Court")...relief under Chapter 11 of the United States Bankr...he orders issued by the Bankruptcy Court allow the...
(Date:11/24/2009)... Nov. 24 Blue Marble Energy Corp. ...blic Development Authority (OPDA) were recently aw...conomic Revitalization Board (CERB) in a private/p...pecialty biochemical biorefinery in Lincoln County...speed the development of our biorefinery and bring...
(Date:11/24/2009)...LIN, November 24 Shire p...ty biopharmaceutical company, today,announced that...Agency for,velaglucerase alfa, the company,s enzym...ment of Type 1 Gaucher disease. This is the third ...has been submitted, with previous,submissions in t...
(Date:11/24/2009)... Program Connects Customers with Partners Val...th DNA Genotek Products , ...tek , a leading provider of products for biologica..., today announced its new global partner program. ...A Genotek,s partner community and is designed to h...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...llion to $247 Million -, Third Quarter 2008 Highl...73.7% from the third quarter of 2007 -- Total re... from the third quarter of 2007, -- Gross ...uarter of 2007, -- Gross margin of 81.8% compar...AP loss per share for the quarter was $(0.64), -...
...d,(OTC Bulletin Board: DYMC) (the "Company") is an... commercialization of medical cannabis-based,pharm...o announce it has,signed an agreement to acquire a...fornia group operated by Medical Cannabis pioneer ...w.kubby.com ). The asset purchase agreement,includ...
...I,Respiratory Equipment will present a comparative...anced nebulizers and their in-vitro,performance an...pension,(Pulmicort Respules, AstraZeneca)., "Our ... is to help,clinicians consider respirable drug de...effective doses," said Lisa Cambridge, director of...
Other Biology Technology:Nuvasive Reports Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 3Nuvasive Reports Third Quarter 2008 Financial Results 4Nuvasive Reports Third Quarter 2008 Financial Results 5Nuvasive Reports Third Quarter 2008 Financial Results 6Nuvasive Reports Third Quarter 2008 Financial Results 7Nuvasive Reports Third Quarter 2008 Financial Results 8Nuvasive Reports Third Quarter 2008 Financial Results 9Nuvasive Reports Third Quarter 2008 Financial Results 10Nuvasive Reports Third Quarter 2008 Financial Results 11Nuvasive Reports Third Quarter 2008 Financial Results 12Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 2Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 3
(Date:11/24/2009)...ailable in Spanish . , The presence of incr...lammatory substances in the blood, hinders the los...search project of the University of Navarra conduc...e School of Pharmacy. , The project, entitled "A...o the control of body weight and inflammation," ex...
(Date:11/23/2009)... 23, 2009 - The time of day matters to forest tree...roduced by a research team led by Professor Malcol...ce-principal for research and colleagues in the de...orge campus. , Capitalizing on their previous ...research team examined how poplar trees use their ...
(Date:11/23/2009)...A new study provides "incontrovertible evidence" t...and of Sumatra about 73,000 years ago deforested m...icenter, researchers report. , The volcano eject...he atmosphere, leaving a crater (now the world,s l...and 35 kilometers wide. Ash from the event has bee...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2Time of day matters to thirsty trees, U of T researcher discovers 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Stimulus funding helps K State bring undergrads to prairie for ecology molecular biology research 9710 1Sagent Pharmaceuticals Announces Launch of Fluconazole Injection in Premix Ready to Use IV Bags 55516 1Sagent Pharmaceuticals Announces Launch of Fluconazole Injection in Premix Ready to Use IV Bags 55516 2Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 55512 1Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 55512 2Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 55512 3Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 55512 4
...g technology, which can spot cracks in space shutt...velope and detect tumors without harmful radiation...nal meeting of the American Chemical Society. , Th...arles A. Schmuttenmaer , professor of chemistry ...r of the Center for Terahertz Research at Renssela...
...sity of Texas Medical Branch at Galveston (UTMB) h...n the hepatitis C virus and liver cancer. , The mo... the human papilloma virus (HPV), the cause of gen...Stanley M. Lemon, the senior author of a paper on ...the online early edition of the Proceedings of the...
...from researchers at Harvard Medical School and Mas...closed at the 13th European Cancer Conference (ECC...g delivery is possible using nanoparticle-apatamer...as aptamers) are short DNA or RNA fragments that c...nd affinity; analogous to monoclonal antibodies. I...
Other Biology News:T-rays: New imaging technology spotlighted by American Chemical Society 2Texas scientists discover how a hepatitis C protein promotes liver cancer 2Researchers use 'trickery' to create immune response against melanoma 2Researchers use 'trickery' to create immune response against melanoma 3Researchers use 'trickery' to create immune response against melanoma 4
... the New FAST(tm) Frame Multi-Slide Plate! ,FAS...our, 16-pad FAST Slides and the corresponding mult...nt for high throughput processing of microarrays. ...ended by the Society of Biomolecular Screening.,...
...onal Package Superior Protein Detection and Quant...D Proteomic Imaging System is a highly sensitive i...fe science research applications. ProXPRESS 2D pro...f all dyes in the UV and VIS spectrum range with i...
Northern BoundTM Human Alzheimer's Total RNA Blot from Sigma-Aldrich
..., Rabbit, and media. Cryo-preserved cells in mediu...pprox), supplied with kit (500 mL) of optimized me...culture, and is guaranteed to provide an additiona...lied, when used with the recommended medium. ,So...
Biology Products: